Chimerix Inc. (NASDAQ:CMRX) shares were down 2.7% on Thursday . The company traded as low as $4.63 and last traded at $4.68, with a volume of 244,885 shares trading hands. The stock had previously closed at $4.81.

A number of research analysts have weighed in on CMRX shares. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research note on Tuesday, May 10th. Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the company a “buy” rating in a research note on Thursday, August 18th. Zacks Investment Research cut shares of Chimerix from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and issued a $7.00 target price on shares of Chimerix in a research note on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $15.72.

The stock’s market cap is $213.51 million. The stock has a 50 day moving average of $4.28 and a 200-day moving average of $4.81.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.12. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.98 million. On average, equities analysts anticipate that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.

In other news, Director Ernest Mario purchased 50,000 shares of the stock in a transaction on Friday, June 24th. The shares were acquired at an average price of $3.70 per share, with a total value of $185,000.00. Following the completion of the acquisition, the director now directly owns 381,440 shares of the company’s stock, valued at $1,411,328. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO M Michelle Berrey purchased 13,188 shares of the stock in a transaction on Friday, June 24th. The shares were purchased at an average cost of $3.69 per share, for a total transaction of $48,663.72. Following the acquisition, the chief executive officer now directly owns 258,821 shares of the company’s stock, valued at $955,049.49. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Chimerix stock. Jennison Associates LLC boosted its stake in shares of Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned about 2.76% of Chimerix worth $11,400,000 as of its most recent SEC filing.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.